Lundbeckford Ventures

Globe
Biotech

Novo powers transatlantic rare disease fund to $124M first close

Led by VCs who spent years at Lundbeckfonden and NEA, Sound Bioventures will back biotechs that are either in or on the cusp of the clinic.
Nick Paul Taylor Jan 4, 2022 7:40am
Nasdaq

Ovid seeks metamorphosis into public company with $86M IPO

Apr 12, 2017 4:32am